NasdaqCM - Delayed Quote USD

Benitec Biopharma Inc. (BNTC)

Compare
10.32 -0.48 (-4.44%)
At close: 4:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BNTC

Recent News: BNTC

View More
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Benitec Biopharma Announces Updated Investor Webcast Information

Benitec Biopharma Announces Updated Investor Webcast Information
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc

Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans

Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
View More

Related Tickers